MedPath

Effect of Edaravone in prevention of contrast-induced acute kidney injury (CI-AKI)

Phase 3
Recruiting
Conditions
Contrast induced nephropathy acute kidney injury (CIN-AKI).
Other injury of kidney
S37.09
Registration Number
IRCT20201108049311N5
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Candidates for coronary angiography
Patients with kidney injury stage 4 and Stage 3B with GFR between 15 and 45
Patients with underlying diseases such as diabetes and lupus that cause renal failure

Exclusion Criteria

Pregnancy
lactation
Age over than 75 years
5-fold increased liver enzymes

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum creatinine level. Timepoint: Day 5 of contrast injection. Method of measurement: Biochemical methods.;Hospitalization duration. Timepoint: Number of hospitalization days after angiography. Method of measurement: Patients' documents.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath